Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role Ali  None  N/A  N/A Andrey  None  N/A  N/A Bauml  Clovis, Bristol‐Myers Squibb, Astra Zeneca, Celgene, Boehringer  Honorarium  Consultant Ingleheim, Merck, Guardant Health, Genentech Sciences  Merck, Clovis, Carevive Systems, Novartis, Bayer Pharmaceutics  Research Support  Principal Investigator company Birchard  None  N/A  N/A Bollin  None  N/A  N/A Botta  None  N/A  N/A Costantini  None  N/A  N/A Durand  None  N/A  N/A El‐Khoueiry  None  N/A  N/A Eng  Bayer Healthcare, Sirtex  Honorarium  Consultant

 Genentech, Roche, Bayer Healthcare  Honorarium  Speaker

 Daiichi pharmaceutical Keryx  Grant  Research Support Garcia  Daiichi Sankyo Company, Ltd., Bayer Pharmaceutics company,  Research Support  Principal Investigator Janssen Pharmaceuticals, Inc. Gertz  Alnylam, Prothena Corp  Honorarium  Consultant  Ionis, WebMD, Physicians Education Resource, Amgen, Pharmacyclics,  Honorarium  Speaker Janssen  Janssen, Celgene  Honorarium  Advisory Board

 Appellees  Honorarium  Research Grubbs  None  N/A  N/A Hassell  Pfizer Inc.  Honorarium  Steering Committee Horn  Bristol‐Myers Squibb, Lilly, AstraZeneca, AbbVie, Merck,  Honorarium  Advisory Board  Genentech Sciences  BMS, Lilly, AZ, AbbVie, Merck,  Honorarium  Consultant  Genentech, Xcovery, Bayer, Janssen Hudson  None  N/A  N/A

Hurvitz  Lilly, Novartis, OBI Pharma, Bayer  Honorarium  Speaker  Amgen, Bayer Pharmaceutics company,Boehringer Ingelheim, Genentech Sciences, GlaxoSmithKline,Eli Lilly, Novartis, Pfixer, Roche, PUMA, Merrimack,  Grant  Research Medication, Dignitana, OBI Pharma, Inc., BioMarin Pharmaceutical, Cascadian Therapeutics Seattle Genetics Kantarjian  Amgen, ARIAD Pharmaceuticals, Astec, Inc, Bristol‐Myers Squibb,  Grants  Research Norvartis, Pfizer  AbbVie, Amgen, ARIAD Pharmaceuticals, Bristol‐Myers  Honorarium  Consultant Squibb, Orsenex, Pfizer, ImmunoGen Kelton  None  N/A  N/A Kim  AstraZeneca, Celgene, Eli Lilly,  Research Grant/  Consultant Boehringer Ingelheim Honorarium Kitchens  None  N/A  N/A Kosty  EMD Serono, Merck, Genentech  Grants  Research Support Sciences, Amgen  Biocept  Consulting Fees  Consultant Mahindra  Amgen  Honorarium  Advisory Board

 Sanofi Aventis  Honorarium  Speaker  Celgene; Millennium  Grants  Research Funding pharmaceuticals Malekirad  None  N/A  N/A Mason  Gilead Sciences  Honorarium  Speaker McAneny  None  N/A  N/A McArthur  Amgen , Celgene , Merck , OBI Pharma, Inc, Spectrum Pharmaceuticals, Syndax  Honorarium  Consultant/Advisory Pharmaceuticals, Roche, Peregrine, Board Calithera, TapImmune  Bristol‐Myers Squibb, Eli Lilly ,  Honorarium  Research MedImmune, AstraZeneca , Merck Moll  None  N/A  N/A O'Shaughnessy  AstraZeneca, Pfizer, Eli Lilly, Novartis  Will disclose on‐site  Will disclose on‐site Quinn  None  N/A  N/A Reeves  None  N/A  N/A Saven  Celgene Corporation, Gilead Sciences,Incyte, Millennium Pharmaceuticals,Inc., Onyx  Honorarium  Speakers Bureau Pharmaceuticals, Inc., Pharmacyclics, Seattle Genetics Schuster  •Seattle Genetics, Janssen, Novartis,  Research support, Merck, Genentech Sciences , Nordic  Honorarium consultant, Advisory board Nanovecto

 Gilead Sciences  Honorarium  Consultant, Advisory board

 Research support,  Celgene, Pharmacyclics  Honorarium consultant, advisory board, steering committee Stover  None  N/A  N/A Tarhini  Celgene Corporation, Gilead Sciences Inc., Incyte Corporation, Seattle  Honorarium  Speaker/Advisor Genetics  Bristol‐Myers Squibb, Merck, Amgen,  Grant  Research Prometheus, Incyt Torrey  None  N/A  N/A Wang  Abbvie, Arog Pharmaceuticals,  Honorarium  Advisory board Celgene, Agios, Pfizer, Takeda  Incyte Corporation, Novartis, Jazz  Honorarium  Speaker Pharmaceuticals  Immunogen  Honorarium  Advisory Board, Research Warkentin  Aspen Global Bayer , WL Gore, Law firm, Instrumentation Laboratory,  Honorarium  Consultant Octapharma Xavier  Celgene Corporation, Gilead Sciences Inc., Incyte Corporation, Seattle  Honorarium  Speaker/Advisor Genetics CME Review  None  N/A  N/A Committee Peer Reviewer Botta  None  N/A  N/A Peer Reviewer  None  N/A  N/A Malekirad Scripps Conference  None  N/A  N/A Services & CME

Glossary of Terms Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12‐month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent iny an amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.